m6A-centered Crosstalk Information

Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
Crosstalk ID
M6ACROT05186
 [1]
Non-coding RNA AI662270 WTAP  lncRNA       miRNA   circRNA Direct Enhancement m6A modification CTGF CTGF WTAP Methylation : m6A sites
m6A Modification:
m6A Regulator Wilms tumor 1-associating protein (WTAP) WRITER
 Regulator Info 
m6A Target CCN family member 2 (CTGF)
 Targert Gene 
Epigenetic Regulation that have Cross-talk with This m6A Modification:
Epigenetic Regulation Type Non-coding RNA (ncRNA)
Epigenetic Regulator AI662270 LncRNA View Details
Regulated Target Pre-mRNA-splicing regulator WTAP (WTAP) View Details
Crosstalk Relationship ncRNA  →  m6A Enhancement
Crosstalk Mechanism ncRNAs directly impacts m6A modification through recruiting m6A regulator
Crosstalk Summary AI662270 promotes CCN family member 2 (CTGF) expression at the posttranscriptional stage by recruiting PTM (METTL14, WTAP, METTL3 and KIAA1429) to the CTGF promoter and depositing m6A modifications on the nascent mRNA, thereby, uncovering a novel regulatory mechanism of CTGF in the pathogenesis of kidney fibrosis.
Responsed Disease Chronic kidney disease ICD-11: GB61
 Disease Info 
In-vitro Model
SV40 MES 13
 N.A. Mus musculus CVCL_5368
NRK-52E Normal Rattus norvegicus CVCL_0468
In-vivo Model For the UUO model, the left ureter was exposed via a midline incision and ligated twice 15 mm below the renal pelvis with 4-0 silk after anesthetization. The sham group was similarly handled without ureteral ligation. For the renal IRI model, bilateral renal arteries were clamped for 30 min.
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
CCN family member 2 (CTGF) 3 Compound(s) Regulating the Target Click to Show/Hide the Full List
 Compound Name PF-06473871 Phase 2 [2]
MOA Inhibitor
External Link
TTD: D2AYS0
 Compound Name RXI-109 Phase 2 [3]
Synonyms
A45sd-RxNA
    Click to Show/Hide
MOA Inhibitor
External Link
TTD: D4ZLC2
 Compound Name OLX10010 Phase 2 [4]
Synonyms
OLX 101A
    Click to Show/Hide
MOA Inhibitor
External Link
TTD: DHB2K8
GB61: Chronic kidney disease 15 Compound(s) Regulating the Disease Click to Show/Hide the Full List
 Compound Name Finerenone Approved [5]
Synonyms
UNII-DE2O63YV8R; BAY 94-8862; 1050477-31-0; BAY94-8862; DE2O63YV8R; Finerenone [USAN:INN]; Finerenone (JAN/USAN/INN); SCHEMBL8157011; GTPL8678; DTXSID10146928; J3.584.878I; D10633; 1,6-Naphthyridine-3-carboxamide, 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-1,4-dihydro-2,8-dimethyl-, (4S)-;1,6-Naphthyridine-3-carboxamide, 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-1,4-dihydro-2,8-dimethyl-, (4S)-; 1,6-Naphthyridine-3-carboxamide, 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-1,4-dihydro-2,8-dimethyl-, (4S)-; (4S)-4-(4-cyano-2-metho
    Click to Show/Hide
External Link
CID: 60150535
TTD: D0NV5O
 Compound Name Doxercalciferol Approved [6]
Synonyms
Doxcercalciferol; Hectorol; Doxercalciferol [INN]; TSA 840; BCI-101; Doxercalciferol (INN); Hectorol (TN); (1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5R)-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol; (5Z,7E,22E)-9,10-Secoergosta-5,7,10(19),22-tetraene-1alpha,3beta-diol; 1-Hydroxyergocalciferol; 1-alpha-Hydroxyvitamin D2; 1alpha-Hydroxyergocalciferol; 1alpha-OH-D2; 9,10-Secoergosta-5,7,10(19),22-tetraene-1,3-diol,(1-alpha,3-beta,5Z,7E,22E)
    Click to Show/Hide
External Link
CID: 5281107
TTD: D0G5CF
DrugBank: DB06410
 Compound Name Ferumoxytol Approved [7]
Synonyms
MAGNETITE; Magnetic oxide; Ferrosoferric oxide; Magnetite (Fe3O4); Magnetic Black; Iron Black; Fenosoferric oxide; Black Iron BM; Meramec M 25; Black Gold F 89; RB-BL; 11557 Black; CCRIS 4376; H 3S; EPT 500; EINECS 215-169-8; KN 320; 1309-38-2; iron(ii; ferro ferric oxide; ferric ferrous oxide; Iron ores, magnetite; Ferumoxytol [USAN]; Eisen(II,III)-oxid; KBC 100 (mineral); Code 7228; CHEBI:50821; 1317-61-9 (Parent); LS-88610; 174794-75-3; 122303-97-3; 90577-09-6; 73904-98-0; 151820-32-5; 137263-94-6; 124364-57-4
    Click to Show/Hide
External Link
CID: 14789
TTD: D06CTM
 Compound Name Ferric citrate Approved [8]
Synonyms
Nephoxil; Serene; Zerenex; JTT-751; KRX-0502; PBF-1681; Hyperphosphatemia therapy, Panion/Keryx
    Click to Show/Hide
External Link
CID: 61300
TTD: D04CJL
DrugBank: DB09162
 Compound Name REACT Phase 3 [9]
External Link
TTD: D2QVG7
 Compound Name US-APR2020 Phase 2/3 [10]
External Link
TTD: D3YKX2
 Compound Name ALLN-346 Phase 2 [11]
External Link
TTD: DG31WX
 Compound Name Runcaciguat Phase 2 [12]
Synonyms
(3S)-3-(4-Chloro-3-(((2S,3R)-2-(4-chlorophenyl-4,4,4- trifluoro-3-methylbutanoyl)amino)phenyl)-3- cyclopropylpropanoic acid; (3S)-3-(4-chloro-3-{[(2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino}phenyl)-3-cyclopropylpropanoic acid; (3S)-3-[4-chloro-3-[[(2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino]phenyl]-3-cyclopropylpropanoic acid; 1402936-61-1; 5EZ01YDT5S; AC-37098; AKOS040742586; BAY 1101042; BAY1101042; BAY-1101042; BENZENEPROPANOIC ACID, 4-CHLORO-3-(((2S,3R)-2-(4-CHLOROPHENYL)-4,4,4-TRIFLUORO-3-METHYL-1-OXOBUTYL)AMINO)-.BETA.-CYCLOPROPYL-, (.BETA.S)-; Benzenepropanoic acid, 4-chloro-3-(((2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methyl-1-oxobutyl)amino)-beta-cyclopropyl-, (betaS)-; CHEMBL4650322; compound 45 [PMID: 33872507]; CS-0086784; GTPL12359; HY-109136; MS-29070; Runcaciguat; Runcaciguat [INN]; SCHEMBL20075857; UNII-5EZ01YDT5S; XZ7
    Click to Show/Hide
External Link
CID: 134440946
TTD: D2RG4D
 Compound Name GCS-100 Phase 2 [13]
External Link
TTD: D0JW0V
 Compound Name Neo-Kidney Augment Phase 2 [14]
External Link
TTD: D06XFV
 Compound Name LY-2623091 Phase 2 [15]
Synonyms
Chronic renal disease therapy, Eli Lilly
    Click to Show/Hide
External Link
CID: 42636651
TTD: D05RZE
DrugBank: DB15367
 Compound Name AZD1772//RDX5791 Phase 2 [16]
External Link
TTD: D04AIB
 Compound Name LY3016859 Phase 1/2 [17]
Synonyms
TGF-alpha.epiregulin mAb
    Click to Show/Hide
External Link
TTD: D08EIK
 Compound Name ION532 Phase 1 [18]
Synonyms
AZD2373
    Click to Show/Hide
External Link
TTD: DR07FQ
 Compound Name MEDI8367 Phase 1 [19]
External Link
TTD: D37AYZ
References
Ref 1 Long noncoding RNA AI662270 promotes kidney fibrosis through enhancing METTL3-mediated m(6) A modification of CTGF mRNA. FASEB J. 2023 Aug;37(8):e23071. doi: 10.1096/fj.202202012RRR.
Ref 2 A Placebo-controlled Study of PF-06473871 (Anti-Connective Tissue Growth Factor Antisense Oligonucleotide) in Reducing Hypertrophic Skin Scarring. Plast Reconstr Surg Glob Open. 2018 Sep 6;6(9):e1861.
Ref 3 The current state and future directions of RNAi-based therapeutics. Nat Rev Drug Discov. 2019 Jun;18(6):421-446.
Ref 4 Clinical pipeline report, company report or official report of Olix Pharmaceuticals.
Ref 5 FDA Approved Drug Products from FDA Official Website. 2022. Application Number: 215341.
Ref 6 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2790).
Ref 7 ClinicalTrials.gov (NCT01942460) Ferumoxytol for Iron-Deficiency Anemia in Chronic Kidney Disease and Peritoneal Dialysis Patients. U.S. National Institutes of Health.
Ref 8 ClinicalTrials.gov (NCT02268994) KRX-0502 (Ferric Citrate) for the Treatment of IDA in Adult Subjects With NDD-CKD. U.S. National Institutes of Health.
Ref 9 ClinicalTrials.gov (NCT05099770) A Phase 3 Randomized Controlled Study of Renal Autologous Cell Therapy (REACT) in Subjects With Type 2 Diabetes and Chronic Kidney Disease (REGEN-006). U.S.National Institutes of Health.
Ref 10 ClinicalTrials.gov (NCT05407389) An Open-Label Rollover Extension Phase 2 Clinical Trial To Evaluate The Long-Term Safety And Efficacy Of KT-301 (Formerly US-APR2020) In Subjects With CKD IV Completing The US-APR2020-01 Study. U.S.National Institutes of Health.
Ref 11 ClinicalTrials.gov (NCT04987294) A Randomized, Double-Blind, Placebo-Controlled Study of ALLN-346 (Engineered Urate Oxidase) in Hyperuricemic Subjects With Gout and Mild to Moderate Chronic Kidney Disease. U.S.National Institutes of Health.
Ref 12 ClinicalTrials.gov (NCT04507061) A Randomized, Double-blind, Placebo-controlled, Multi-center Study to Assess the Safety and Efficacy of Individually Titrated Oral Doses of Runcaciguat in Subjects With Clinical Diagnosis of Chronic Kidney Disease With Diabetes and/or Hypertension and at Least One Cardiovascular Comorbidity. U.S.National Institutes of Health.
Ref 13 ClinicalTrials.gov (NCT01843790) A Phase 2a Study of Weekly Doses of GCS-100 in Patients With Chronic Kidney Disease. U.S. National Institutes of Health.
Ref 14 ClinicalTrials.gov (NCT02525263) Autologous Neo-Kidney Augment (NKA) in Patients With Type 2 Diabetes and Chronic Kidney Disease (CKD) (RMCL-CL001). U.S. National Institutes of Health.
Ref 15 ClinicalTrials.gov (NCT02194465) A Study of LY2623091 in Participants With High Blood Pressure. U.S. National Institutes of Health.
Ref 16 Clinical pipeline report, company report or official report of Ardelyx.
Ref 17 ClinicalTrials.gov (NCT01774981) Study of LY3016859 in Participants With Diabetic Nephropathy. U.S. National Institutes of Health.
Ref 18 ClinicalTrials.gov (NCT05351047) A Phase I, Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD2373 Following Multiple Ascending Dose Administration to Healthy Male Participants of Sub-Saharan West African Ancestry. U.S.National Institutes of Health.
Ref 19 ClinicalTrials.gov (NCT04365218) A Phase I Randomized, Blinded, Placebo-controlled Study to Evaluate the Safety and Pharmacokinetics of MEDI8367 Administered as Single Ascending Doses in Healthy Subjects, and as a Single Dose in Healthy Subjects of Japanese-descent and in Subjects With Chronic Kidney Disease. U.S.National Institutes of Health.